---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/38224102.md"
description: "Recently looking at Pfizer, it's clearly no longer in the pandemic dividend phase, with market focus largely returning to its core business: pipeline, M&A digestion, and cash flow. The decline in vaccine and oral drug revenue is a consensus, but the company has made significant moves in cost-cutting and pipeline replenishment, resembling a slowly recovering pharmaceutical stock."
datetime: "2026-01-29T13:35:07.000Z"
locales:
  - [en](https://longbridge.com/en/topics/38224102.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/38224102.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/38224102.md)
author: "[大A没救了](https://longbridge.com/en/profiles/7200359.md)"
generator: "portal-rs"
---

# Recently looking at Pfizer, it's clearly no longer…


### Related Stocks

- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)

## Comments (5)

- **Eyoviel · 2026-01-29T13:37:37.000Z**: Pharmaceutical stocks are not favored now
  - **浪漫照进现实** (2026-01-29T13:38:14.000Z): Yes, capital prefers AI and technology, while pharmaceuticals are more defensive
- **雷神之子 · 2026-01-29T13:37:22.000Z**: Is the asset it previously spent a lot of money on worth it now?
- **无名小卒之小小卒 · 2026-01-29T13:37:09.000Z**: Without COVID-related income, is the fundamental situation looking bad?
  - **浪漫照进现实** (2026-01-29T13:37:59.000Z): It will definitely look bad in the short term, but the market already knew this. The key is whether it can stabilize the foundation.


---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**